Full Text View
Tabular View
No Study Results Posted
Related Studies
Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan (SAFIR)
This study has been completed.
Study NCT00791830   Information provided by University of Aarhus

First Received on November 14, 2008.   Last Updated on January 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Failure, Chronic
Additional conditions recognized in this trial
Renal Insufficiency
More general conditions related to this trial
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
Irbesartan
Placebo matching irbesartan 150 mg
Additional drug interventions recognized in this trial
Angiotensin II Type 1 Receptor Blockers
More general drug interventions related to this trial
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
University of Aarhus


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services